Your browser is no longer supported. Please, upgrade your browser.
Settings
KDMN Kadmon Holdings, Inc. daily Stock Chart
KDMN [NYSE]
Kadmon Holdings, Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own3.73% Shs Outstand107.01M Perf Week-0.59%
Market Cap361.69M Forward P/E- EPS next Y-0.73 Insider Trans0.00% Shs Float104.92M Perf Month-1.46%
Income-41.20M PEG- EPS next Q-0.23 Inst Own70.90% Short Float5.89% Perf Quarter-9.87%
Sales4.50M P/S80.38 EPS this Y85.30% Inst Trans63.83% Short Ratio7.11 Perf Half Y-6.89%
Book/sh1.15 P/B2.94 EPS next Y-49.00% ROA-38.40% Target Price11.58 Perf Year46.96%
Cash/sh1.23 P/C2.75 EPS next 5Y- ROE- 52W Range2.16 - 5.86 Perf YTD-6.63%
Dividend- P/FCF- EPS past 5Y- ROI1464.60% 52W High-42.75% Beta-
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin56.80% 52W Low55.32% ATR0.14
Employees103 Current Ratio3.10 Sales Q/Q-86.70% Oper. Margin- RSI (14)46.45 Volatility4.83% 3.93%
OptionableYes Debt/Eq0.29 EPS Q/Q153.80% Profit Margin- Rel Volume0.39 Prev Close3.38
ShortableYes LT Debt/Eq0.00 EarningsAug 09 Payout- Avg Volume869.33K Price3.36
Recom2.30 SMA20-0.19% SMA50-5.84% SMA200-13.47% Volume238,487 Change-0.74%
Mar-16-17Upgrade WBB Securities Sell → Hold $3.25
Mar-14-17Initiated Piper Jaffray Overweight
Aug-09-18 04:15PM  Kadmon Provides Business Update and Reports Second Quarter 2018 Financial Results Business Wire
Jun-21-18 08:25AM  Analysis: Positioning to Benefit within Second Sight Medical Products, ICF International, Morningstar, Spark Therapeutics, Natera, and Kadmon Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-15-18 09:00AM  Kadmon Announces Updated Results of KD025 in cGVHD at EHA Congress Business Wire
Jun-14-18 04:15PM  Kadmon Announces Closing of $113.2 Million Offerings of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares Business Wire
Jun-12-18 12:45PM  Here's Why Kadmon Shot Higher Today Motley Fool +9.85%
Jun-11-18 07:55PM  Kadmon Announces Pricing of Offerings of Common Stock Business Wire
04:01PM  Kadmon Announces Proposed Public Offering of Common Stock Business Wire
May-31-18 09:00AM  Kadmon to Present at the Jefferies 2018 Global Healthcare Conference Business Wire
May-17-18 09:02AM  Kadmon Announces Oral Presentation on KD025 in cGVHD at EHA Congress Business Wire
May-08-18 04:15PM  Kadmon Provides Business Update and Reports First Quarter 2018 Financial Results Business Wire
May-01-18 07:35AM  Analysis: Positioning to Benefit within USA Compression Partners, LP, Kadmon, Repligen, Independent Bank, Leggett & Platt, and Esterline Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-10-18 08:00AM  Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease Business Wire +6.03%
Mar-06-18 04:15PM  Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results Business Wire
Feb-26-18 07:10AM  Wired News Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings ACCESSWIRE
Feb-22-18 06:45PM  Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD Business Wire
Feb-13-18 07:37PM  Why Karmon's "Positive" Data Turned Into a 21% Decline Motley Fool -21.28%
04:30PM  Why Molina Healthcare, Brighthouse Financial, and Kadmon Holdings Slumped Today Motley Fool
11:49AM  Vertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech Movers Market Exclusive
08:10AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Feb-12-18 09:11PM  Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF Business Wire
04:06PM  Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis Business Wire
Jan-15-18 08:41AM  Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3% Zacks
Jan-05-18 08:30AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Virtu Financial, Tableau Software, Graco, Kadmon, and Titan International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-20-17 11:49AM  ETFs with exposure to Kadmon Holdings, Inc. : December 20, 2017 Capital Cube
Dec-10-17 09:00AM  Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting Business Wire
Nov-30-17 02:02PM  ETFs with exposure to Kadmon Holdings, Inc. : November 30, 2017 Capital Cube
Nov-29-17 07:55AM  Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 09:00AM  Kadmon to Present at the 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-17 09:00AM  Kadmon to Present at the Jefferies 2017 London Healthcare Conference Business Wire
Nov-13-17 09:00AM  Kadmon Initiates Phase 2 Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease Business Wire
Nov-09-17 04:01PM  Kadmon Provides Business Update and Reports Third Quarter 2017 Financial Results Business Wire
Nov-01-17 09:00AM  Kadmon to Present New Data from Ongoing Phase 2 Study of KD025 in cGVHD at ASH Annual Meeting Business Wire
Oct-10-17 07:10AM  Featured Company News - Kadmon Holdings' KD025 Receives Orphan Drug Designation for the Treatment of cGVHD by FDA ACCESSWIRE
Oct-06-17 08:11AM  FDA Grants Orphan Drug Designation to Kadmons KD025 for the Treatment of cGVHD Business Wire
Sep-28-17 09:53AM  Kadmon Announces Closing of $80.4 Million Public Offerings and Full Exercise of Over-Allotment Option Business Wire
Sep-26-17 09:08AM  Kadmon Announces Pricing of Public Offerings of Common Stock and Warrants Business Wire -14.51%
Sep-25-17 04:13PM  Kadmon Announces Proposed Public Offering of Common Stock and Warrants Business Wire +7.67%
Sep-22-17 11:13AM  ETFs with exposure to Kadmon Holdings, Inc. : September 22, 2017 Capital Cube
Sep-06-17 09:00AM  Kadmon to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Business Wire -8.96%
Aug-31-17 07:07PM  ETFs with exposure to Kadmon Holdings, Inc. : August 31, 2017 Capital Cube
Aug-25-17 10:51AM  Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-11-17 09:00AM  Kadmon to Present Preclinical Data on ROCK Inhibition in Pulmonary Fibrosis at IPF Summit 2017 Business Wire
Aug-07-17 09:00AM  FDA Grants Orphan Drug Designation to Kadmons Tesevatinib for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer Business Wire +7.27%
Aug-03-17 04:01PM  Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results Business Wire
Jul-25-17 08:00AM  Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease Business Wire -7.17%
Jul-11-17 08:00AM  Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease Business Wire -9.14%
Jun-30-17 10:50AM  Small Caps Outperform in June: 4 Best ETFs & Stocks Zacks -5.58%
06:13AM  Kadmon Holdings (KDMN) Shares March Higher, Can It Continue? Zacks
Jun-23-17 09:00AM  Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day Business Wire
Jun-22-17 03:55PM  ETFs with exposure to Kadmon Holdings, Inc. : June 22, 2017 Capital Cube
Jun-05-17 02:27PM  ETFs with exposure to Kadmon Holdings, Inc. : June 5, 2017 Capital Cube
09:00AM  Kadmon to Present at the Jefferies 2017 Global Healthcare Conference Business Wire
Jun-02-17 10:09AM  Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 09:00AM  Kadmon Announces Data Demonstrating the Potential of the Companys New GLUT Inhibitors for the Treatment of Autoimmune and Inflammatory Conditions Business Wire +13.27%
May-22-17 02:14PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of Shareholders Business Wire +10.88%
May-16-17 03:34PM  Scott+Scott, Attorneys at Law, LLP Announces Investigation of Kadmon Holdings Inc. (KDMN) PR Newswire -6.90%
May-15-17 09:00AM  Kadmon Provides Business Update and Reports First Quarter 2017 Financial Results Business Wire
May-11-17 09:00AM  Kadmon to Present Clinical and Preclinical Data Highlighting the Role of ROCK2 Signaling in Immune System Function at AAI Annual Meeting Business Wire
Apr-12-17 09:00AM  Kadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients Business Wire -7.59%
Apr-04-17 09:00AM  Kadmon Submits Second Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA Business Wire
09:00AM  Kadmon Submits Second Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
Apr-03-17 09:06AM  KADMON HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
09:00AM  Kadmon Announces Amendment to Credit Agreement and Related Warrants Business Wire
Mar-29-17 08:32PM  ETFs with exposure to Kadmon Holdings, Inc. : March 30, 2017 Capital Cube
08:32PM  ETFs with exposure to Kadmon Holdings, Inc. : March 30, 2017
Mar-28-17 01:04PM  KADMON HOLDINGS, INC. Financials
09:00AM  Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis Business Wire
Mar-24-17 09:35AM  Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017 Capital Cube
09:35AM  Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017
Mar-22-17 04:06PM  KADMON HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -5.09%
04:01PM  Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results Business Wire
Mar-20-17 04:23PM  Jazz Pharma Isn't Dozing; Stock Breaks Out On Sleep Apnea Trial +12.32%
Mar-16-17 08:36AM  Kadmon Holdings upgraded by WBB Securities
Mar-09-17 06:05AM  KADMON HOLDINGS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Unregistered Sale of Equity S
Mar-08-17 09:06AM  Kadmon Announces Approximately $23 Million Equity Financing Business Wire
Feb-17-17 04:12PM  KADMON HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-20-17 04:02PM  KADMON HOLDINGS, INC. Files SEC form 8-K, Other Events
Jan-18-17 04:02PM  KADMON HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-06-17 04:04PM  KADMON HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers +5.02%
Dec-13-16 04:23AM  Hedge Funds Are Buying Kadmon Holdings LLC (KDMN) Insider Monkey
04:23AM  Hedge Funds Are Buying Kadmon Holdings LLC (KDMN) at Insider Monkey
Dec-06-16 09:15AM  KADMON HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases Business Wire
Dec-05-16 04:09PM  KADMON HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:01PM  Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA Business Wire
Nov-28-16 08:30AM  Kadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-21-16 08:48AM  KADMON HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-19-16 11:15AM  Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016 Business Wire
Nov-14-16 08:30AM  Kadmon to Present at the Jefferies 2016 London Healthcare Conference Business Wire
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDENTREE ASSET MANAGEMENT LP10% OwnerSep 06Sale2.72200,000544,000103,502Sep 07 07:26 PM
GOLDENTREE ASSET MANAGEMENT LP10% OwnerSep 05Sale2.76100,000276,010107,054Sep 07 07:26 PM